Houston Oncology Summit: MD Anderson Professor of Immunology Michael Curran talks turning cold tumors hot, including work by his company ImmunoGenesis

blonca9
Sep 26, 2024
1 min read

He discusses pathways that could play a role in helping solve this problem, including combinations with ADCs, STING and CD47, and work by his company ImmunoGenesis on a PD-L1/PD-L2 inhibitor

Brought to you by:

Recent Posts

See All

Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

Houston Oncology Summit: MD Anderson Professor of Immunology Michael Curran talks turning cold tumors hot, including work by his company ImmunoGenesis

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight